Motor OFF Episodes Associated With Parkinson's Disease
Conditions
Keywords
Parkinson's Disease, Off Episodes, motor fluctuations associated with Parkinson's Disease
Brief summary
A study of an investigational drug to see how it affects the people with Parkinson's Disease complicated by motor fluctuations (OFF Episodes) compared to an approved drug used to treat people with Parkinson's Disease complicated by motor fluctuations (OFF Episodes)
Detailed description
An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated by Motor Fluctuations. PART A consists of an open label, crossover titration phase where eligible subjects will be randomized to 1 of 2 treatment sequences in a 1:1 ratio to Sublingual APL-130277 followed by subcutaneous apomorphine or subcutaneous apomorphine followed by sublingual APL-130277. Subjects will undergo dose titration with the first study treatment (APL-130277 or sc apomorphine) to tolerance and effect, ie, the tolerable dose that turns the subject from the practically defined OFF state to the full ON state as determined by both the Investigator and subject. The subject will then be crossed over to the other study treatment (APL-130277 or subcutaneous apomorphine) and similarly titrated to tolerance and effect. These determined doses of APL-130277 and subcutaneous apomorphine will be used during PART B. PART B consists of an open-label, crossover treatment period where subjects will be randomized to one of the study treatment for 4 weeks, then be crossed over to the other study treatment (APL-130277 or sc apomorphine) for additional 4-weeks of open-label treatment. Subjects return to the clinic for safety and efficacy assessments throughout the treatment period. This study is designed to test the superiority of sublingually administered APL-130277 against subcutaneously injected apomorphine (APO-go) for the treatment of OFF episodes in patients with Parkinson's Disease, as measured by the change from pre-dose to 90 minutes post-dose in MDS UPDRS Part III score in Part B after 4 weeks of dosing in each crossover period.
Interventions
DRUGAPL-130277
APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
DRUGsubcutaneous apomorphine
subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
Sponsors
Sumitomo Pharma America, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Masking description
Open label: APL-130277 and Subcutaneous Apomorphine Single-Blinded Rater for MDS-UPDRS Part III Motor Examination assessment in Part B.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The subject (and caregiver, if applicable) must be fully informed of and understand the objectives, procedures, and possible benefits and risks of the study, and give written informed consent prior to performing any study related activities. 2. Male or female ≥ 18 years of age. 3. Clinical diagnosis of Idiopathic Parkinson's disease (PD), consistent with UK Brain Bank Criteria (excluding the more than one affected relative criterion). 4. Clinically meaningful response to levodopa (L-Dopa), as determined by the Investigator. 5. Subjects at screening must demonstrate an adequate L-Dopa response on the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS UPDRS) Part III in the ON state compared to the MDS UPDRS Part III in the OFF state and on the Hoehn and Yahr, as determined during the review by Enrollment Adjudication Committee (EAC), Sponsor, and Medical Monitor. 6. Receiving stable doses of L Dopa/carbidopa and/or L Dopa/benserazide and/or L Dopa/carbidopa/entacapone (immediate or chronic release) administered at least 4 times per day OR Rytary™ administered at least 3 times per day for at least 4 weeks before the initial screening Visit (SV1). Adjunctive PD medication regimens are permitted but must be maintained at a stable dose for at least 4 weeks prior to SV1 with the exception of monoamine oxidase B (MAO B) inhibitors, which must be maintained at a stable level for at least 8 weeks prior to SV1. 7. No planned medication change(s) or surgical intervention anticipated during the course of study. 8. Subjects must experience at least one well defined OFF episode per day and have a total daily OFF time duration of \> 2 hours during the waking day, based on judgment of physician and subject self assessment. 9. Subject must have predictable morning OFF periods, based on judgment of physician and subject self assessment. 10. Subject, and where appropriate caregiver, must be trained in completing the home dosing diaries and able to recognize ON and OFF states. 11. Stage III or less on the modified Hoehn and Yahr scale in the ON state. 12. Mini-Mental State Examination (MMSE) score \> 25. 13. Female subject of childbearing potential and male subject with female partner of childbearing potential must agree to either remain abstinent or use adequate and reliable contraception throughout the study and for at least 7 days after the last dose of study drug has been taken. Note: Continued use of adequate and reliable contraception is recommended through 30 days after study completion. 14. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study related procedures to complete the study. 15. Must be approved as a satisfactory candidate by the Enrollment Adjudication Committee (EAC), Medical Monitor, and Sponsor.
Exclusion criteria
1. Atypical or secondary parkinsonism. 2. Major focal brain disorders including malignancy or stroke. 3. Prior treatment with any of the following: a neurosurgical procedure for PD; continuous subcutaneous (subcutaneous) apomorphine infusion; subcutaneous (subcutaneous) apomorphine injection; Duodopa/Duopa; or APL-130277. 4. Contraindications to domperidone, subcutaneous apomorphine, or hypersensitivity to apomorphine hydrochloride or any of the ingredients of subcutaneous apomorphine (notably sodium metabisulfite). 5. Female who is pregnant or lactating. 6. Participation in an interventional clinical study and/or receipt of any investigational (ie, unapproved) medication within 30 days prior to SV1. 7. Currently taking selective 5HT3 antagonists (ie, ondansetron, granisetron, dolasetron, palonosetron, alosetron), dopamine antagonists (excluding quetiapine or clozapine) or dopamine depleting agents. Subjects receiving anti depressants must be on a stable daily dose for at least 8 weeks prior to SV1. 8. The subject has a current diagnosis or history of substance abuse (excluding nicotine and caffeine) or alcohol abuse (in the opinion of the investigator) \< 6 months prior to SV1. 9. The recreational use of cannabinoids and hallucinogenic are excluded, as well any use of a sublingual formulation of any drug. 10. Subject has a history of malignancy within 5 years prior to SV1, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. 11. Subject has a clinically significant abnormality on screening evaluation including physical examination, vital signs, electrocardiogram (ECG), or laboratory tests that the Investigator considers to be inappropriate to allow participation in the study. 12. Subject has screening laboratory test results of: blood urea nitrogen (BUN) value ≥ 1.5 times the upper limit of normal (ULN) for the reference range; serum creatinine \> 1.5 times the ULN for the reference range; or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value ≥ 2 times the ULN for the reference laboratory. 13. Subject has random (non-fasting) screening glucose of ≥ 200 mg/dL (11.1 mmol/L) or HbA1c \> 7.0%. 14. Subjects with type 1 diabetes, or insulin dependent diabetics are excluded. Subjects with type 2 diabetes are eligible for study inclusion if the following conditions are met: * Subject's screening glucose is \< 200 mg/dL (11.1 mmol/L). Note: Subjects with random (non fasting) blood glucose at screening ≥ 200 mg/dL (11.1 mmol/L) must be retested in a fasted state; and * Subject's hemoglobin A1c (HbA1c) ≤ 7.0%; and * If the subject is currently being treated with oral anti-diabetic medication(s), the dose must have been stable for at least 4 weeks prior to SV1. Such medication may be adjusted or discontinued during the study, as clinically indicated. 15. The subject's screening ECG results of corrected QT interval using Fridericia's formula (QTcF) ≥ 450 msec for male subjects or ≥ 470 msec for female subjects. Eligibility will be based on the core laboratory ECG interpretation report. 16. Subject has a positive screening laboratory test result for human immunodeficiency virus (HIV). 17. Subject has a positive screening laboratory test result for hepatitis B surface antigen or hepatitis C antibodies and has liver function test results at screening above the ULN for the reference laboratory. 18. Subject has any other medical disorder that, in the opinion of the Investigator, could interfere with the subject's participation in the study. 19. Subject has major psychiatric disorder(s), including but not limited to: bipolar disorder, psychosis (eg, Parkinson's Disease Psychosis), major depressive episode, or any disorder that, in the opinion of the Investigator, would require treatment that could make study participation unsafe or make treatment compliance difficult. 20. History of clinically significant impulse control disorder(s). 21. History of symptomatic orthostatic hypotension requiring medication. 22. History of severe dyskinesia based on a score of 4 on the MDS-UPDRS Part IV. 23. Dementia that precludes providing informed consent or would interfere with participation in the study. 24. Current/recent suicidal ideation as evidenced by answering yes to Suicidal Ideation item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at screening (using the screening /Baseline Version scale, in the past 12 months) or attempted suicide within the last 5 years. 25. Presence of canker or mouth sores in the 30 days prior to SV1, or other clinically significant oral pathology in the opinion of the Investigator. The Investigator should follow-up with an appropriate specialist on any finding, if indicated, before enrolling a subject into the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Pre-dose to 90 Mins. Post-dose in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Score After 4 Weeks of Dosing in Each Crossover Period (Assessed by the Blinded-rater In-clinic at Visit 3 and Visit 6 of PART B). | Pre-dose to 90 minutes post-dose at Week 4 of each treatment period (Visit 3 and 6) | The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society. The summary score used in this study for the primary objective and primary efficacy endpoint is Part III motor examination score. Each Part III item has a 0-4 rating, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Higher MDS-UPDRS scores reflect worse motor function. MDS-UPDRS III is a total of 18 questions with 33 individual items, each item ranges from 0-4. The MDS-UPDRS III motor score is the summation of all these 33 individual item scores, and hence ranges from 0-132. Score drops over time imply improvement in motor function (higher values represent a worse outcome). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Durability of Effect, Defined as an Investigator Confirmed Full ON Within 30 Minutes Post Dose and at 90 Minutes Post-dose, After 4 Weeks of Dosing in Each Crossover Period (Assessed by the Blinded-rater In-clinic at Visit 3 and Visit 6 of PART B). | Within 30 minutes post-dose and at 90 minutes post-dose at Week 4 of each treatment period (Visit 3 and 6) | Investigator will confirm whether subject is OFF, Full ON or Partial ON , and note the time the subject changes from OFF to Partial ON or Full ON. The Investigator will also record the subject ON/OFF status (binary variable, Yes / No) prior to performing each MDS-UPDRS Part III assessment. Durability of effect is defined as an Investigator confirmed full ON within 30 minutes post-dose and at 90 minutes post-dose, after 4 weeks of dosing in each PART B crossover period. Response rate = % of subjects that achived full ON within the timeframe |
| Subject Preference for APL Treatment as Measured by the Subject Treatment Preference Questionnaire (TPQ), Planned After the Subject Had Completed Both APL-130277 and sc Apomorphine Treatment Regimens (Assessed In-clinic at Visit 6 of PART B) | After 8 weeks of treatment (Visit 6) | The TPQ assessment of subject treatment preference was changed from being based on a visual analogue scale or VAS (Q9b)) to a 5-point Likert scale (Q9a). Subject reported preference for APL or SC was based on question Q9a or Q9b combined. For Q9a, responses were dichotomized as follows for statistical analysis: preference for APL (responses of either definitely or somewhat prefer APL) versus no preference for APL (responses of no preference, or somewhat/definitely prefer sc apomorphine). The VAS score was similarly dichotomized as preference for APL (score of \>0 to 50) versus no preference for APL (-50 to 0). If a subject responded to both Q9a and Q9b, then Q9a only was used. |
| Subject Confirmed Durability of Effect, Defined as Subject Confirmed Full ON Within 30 Minutes Post-dose and at 90 Minutes Post-dose, After 4 Weeks of Dosing in Each Crossover Period (Assessed In-clinic at Visit 3 and Visit 6 of PART B). | Week 4 | Patients will confirm whether he/she is OFF, Full ON or Partial ON, and the staff will ask the subject to notify the staff when he/she changes from OFF to Partial ON or Full ON (binary variable, Yes / No) . Subject confirmed durability of effect is defined as subject confirmed full ON within 30 minutes post-dose and at 90 minutes post-dose, after 4 weeks of dosing in each crossover period (assessed in-clinic at V3 and V6 of PART B). Response rate = % subjects that achived full ON within the timeframe |
| Patient Global Impression of Change (PGI-C): Subject Improvement of OFF Episodes, Defined as Very Much Better, Much Better or a Little Better After 4 Weeks of Dosing in Each Crossover Period (Assessed In-clinic at Visit 3 and Visit 6 of PART B). | At Week 4 of each treatment period (Visit 3 and 6, or Early Termination) | The PGI-C is the patient reported outcome counterpart to the Clinical Global Impressions scale, (CGI), which was published in 1976 by the National Institute of Mental Health (US). It consists of one item taken from the CGI and adapted to the patient. The PGI-C is based on a 7-point scale, where a lower score is associated with higher symptom improvement. The scale is: Very much better Much better A little better No change A little worse Much worse Very much worse Subject improvement of OFF episodes is defined as very much better, much better or a little better at Week 4 in each PART B crossover period. Response rate= % of subjects who achieved improvement of OFF episodes |
Countries
Austria, France, Germany, Italy, Spain, United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| APL-SC Part A - Titration Phase: APL (APL-130277) then SC (subcutaneous apomorphine); Did not continue in Part B - Treatment Phase. | 20 |
| SC-APL Part A - Titration Phase: SC (subcutaneous apomorphine) then apomorphine hydrochloride APL (APL-130277); Did not continue in Part B - Treatment Phase. | 18 |
| APL-SC-APL-SC Part A - Titration Phase: APL (APL-130277) then SC (subcutaneous apomorphine) into Part B - Treatment Phase: APL then SC | 19 |
| APL-SC-SC-APL Part A - Titration Phase: APL (APL-130277) then SC (subcutaneous apomorphine); Randomized into Part B - Treatment Phase: SC then APL | 18 |
| SC-APL-APL-SC Part A - Titration Phase: SC (subcutaneous apomorphine) then APL (APL-130277); Randomized into Part B - Treatment Phase: APL then SC | 18 |
| SC-APL-SC-APL Part A - Titration Phase: SC (subcutaneous apomorphine) then APL (APL-130277); Randomized into Part B - Treatment Phase: SC then APL | 19 |
| Total | 112 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Part A - Titration Phase | Adverse Event | 3 | 6 | 0 | 0 | 0 | 0 |
| Part A - Titration Phase | EARLY TERM AT SPONSOR REQUEST | 0 | 1 | 0 | 0 | 0 | 0 |
| Part A - Titration Phase | Lack of Efficacy | 12 | 6 | 0 | 0 | 0 | 0 |
| Part A - Titration Phase | Withdrawal by Subject | 3 | 3 | 0 | 0 | 0 | 0 |
| Part B - Treatment Phase | Adverse Event | 0 | 0 | 1 | 1 | 3 | 1 |
| Part B - Treatment Phase | Withdrawal by Subject | 0 | 0 | 2 | 2 | 1 | 3 |
| Post Part A / Pre Part B | Lack of Efficacy | 1 | 3 | 0 | 0 | 0 | 0 |
| Post Part A / Pre Part B | Protocol Violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Study Overall | Adverse Event | 3 | 6 | 1 | 1 | 3 | 1 |
| Study Overall | EARLY TERM AT SPONSOR REQUEST | 0 | 1 | 0 | 0 | 0 | 0 |
| Study Overall | Lack of Efficacy | 13 | 9 | 0 | 0 | 0 | 0 |
| Study Overall | Protocol Violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Study Overall | Withdrawal by Subject | 3 | 3 | 2 | 2 | 1 | 3 |
Baseline characteristics
| Characteristic | APL-SC | SC-APL | APL-SC-APL-SC | APL-SC-SC-APL | SC-APL-APL-SC | SC-APL-SC-APL | Total |
|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 11 Participants | 10 Participants | 11 Participants | 8 Participants | 9 Participants | 11 Participants | 60 Participants |
| Age, Categorical Between 18 and 65 years | 9 Participants | 8 Participants | 8 Participants | 10 Participants | 9 Participants | 8 Participants | 52 Participants |
| Age, Continuous | 64.9 Years STANDARD_DEVIATION 8.33 | 63.9 Years STANDARD_DEVIATION 9.99 | 65.0 Years STANDARD_DEVIATION 9.8 | 63.2 Years STANDARD_DEVIATION 6.91 | 63.4 Years STANDARD_DEVIATION 9.71 | 65.6 Years STANDARD_DEVIATION 8.69 | 64.4 Years STANDARD_DEVIATION 8.8 |
| Apomorphine naive at screening N | 1 Participants | 2 Participants | 5 Participants | 2 Participants | 2 Participants | 1 Participants | 13 Participants |
| Apomorphine naive at screening Y | 19 Participants | 16 Participants | 14 Participants | 16 Participants | 16 Participants | 18 Participants | 99 Participants |
| Baseline BMI (kg/m^2) | 26.19 kg/m^2 STANDARD_DEVIATION 4.436 | 25.60 kg/m^2 STANDARD_DEVIATION 4.813 | 26.36 kg/m^2 STANDARD_DEVIATION 5.866 | 26.34 kg/m^2 STANDARD_DEVIATION 4.013 | 28.12 kg/m^2 STANDARD_DEVIATION 6.1 | 26.30 kg/m^2 STANDARD_DEVIATION 4.912 | 26.48 kg/m^2 STANDARD_DEVIATION 5.016 |
| Baseline Height (cm) | 168.05 cm STANDARD_DEVIATION 12.626 | 165.62 cm STANDARD_DEVIATION 12.348 | 171.91 cm STANDARD_DEVIATION 10.26 | 174.78 cm STANDARD_DEVIATION 6.632 | 170.94 cm STANDARD_DEVIATION 9.795 | 171.16 cm STANDARD_DEVIATION 9.929 | 170.39 cm STANDARD_DEVIATION 10.652 |
| Baseline Weight (kg) | 74.25 kg STANDARD_DEVIATION 16.151 | 70.91 kg STANDARD_DEVIATION 18.624 | 78.45 kg STANDARD_DEVIATION 21.893 | 80.31 kg STANDARD_DEVIATION 11.691 | 83.26 kg STANDARD_DEVIATION 24.383 | 77.14 kg STANDARD_DEVIATION 15.284 | 77.34 kg STANDARD_DEVIATION 18.47 |
| Change in MDS-UPDRS Part III Score from Pre-dose to 30 minutes after levodopa dosing at SV2 | -18.0 Units on a scale STANDARD_DEVIATION 12.33 | -16.2 Units on a scale STANDARD_DEVIATION 11.8 | -19.8 Units on a scale STANDARD_DEVIATION 13.64 | -22.9 Units on a scale STANDARD_DEVIATION 12.09 | -21.9 Units on a scale STANDARD_DEVIATION 14.19 | -21.8 Units on a scale STANDARD_DEVIATION 12.53 | -20.1 Units on a scale STANDARD_DEVIATION 12.7 |
| Country Austria | 1 Participants | 0 Participants | 2 Participants | 1 Participants | 1 Participants | 0 Participants | 5 Participants |
| Country France | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants |
| Country Germany | 6 Participants | 2 Participants | 8 Participants | 10 Participants | 5 Participants | 10 Participants | 41 Participants |
| Country Italy | 4 Participants | 6 Participants | 4 Participants | 1 Participants | 5 Participants | 1 Participants | 21 Participants |
| Country Spain | 7 Participants | 8 Participants | 4 Participants | 3 Participants | 5 Participants | 4 Participants | 31 Participants |
| Country United Kingdom | 1 Participants | 1 Participants | 1 Participants | 3 Participants | 2 Participants | 3 Participants | 11 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 3 Participants | 1 Participants | 1 Participants | 2 Participants | 1 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 19 Participants | 15 Participants | 18 Participants | 16 Participants | 16 Participants | 18 Participants | 102 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants |
| Movement Disorders Society Unified Parkinson Part III Score assessed prior to levodopa dosing at SV2 | 53.6 Units on a scale STANDARD_DEVIATION 13.11 | 50.6 Units on a scale STANDARD_DEVIATION 14.74 | 50.3 Units on a scale STANDARD_DEVIATION 12.18 | 50.1 Units on a scale STANDARD_DEVIATION 10.33 | 53.3 Units on a scale STANDARD_DEVIATION 15.2 | 48.6 Units on a scale STANDARD_DEVIATION 13.36 | 51.1 Units on a scale STANDARD_DEVIATION 13.07 |
| Parkinson's disease duration Group <=10 years | 17 Participants | 14 Participants | 11 Participants | 12 Participants | 10 Participants | 11 Participants | 75 Participants |
| Parkinson's disease duration Group >10 years | 3 Participants | 4 Participants | 8 Participants | 6 Participants | 8 Participants | 8 Participants | 37 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 20 Participants | 18 Participants | 19 Participants | 18 Participants | 18 Participants | 19 Participants | 112 Participants |
| Sex: Female, Male Female | 7 Participants | 7 Participants | 6 Participants | 1 Participants | 6 Participants | 7 Participants | 34 Participants |
| Sex: Female, Male Male | 13 Participants | 11 Participants | 13 Participants | 17 Participants | 12 Participants | 12 Participants | 78 Participants |
| Total Daily Levodopa Dose Category (mg) < 900 mg | 15 Participants | 13 Participants | 15 Participants | 14 Participants | 15 Participants | 14 Participants | 86 Participants |
| Total Daily Levodopa Dose Category (mg) >= 900 mg | 5 Participants | 5 Participants | 4 Participants | 4 Participants | 3 Participants | 5 Participants | 26 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 102 | 0 / 97 | 0 / 71 | 0 / 70 |
| other Total, other adverse events | 52 / 102 | 44 / 97 | 23 / 71 | 37 / 70 |
| serious Total, serious adverse events | 0 / 102 | 1 / 97 | 1 / 71 | 1 / 70 |
Outcome results
Primary
Change From Pre-dose to 90 Mins. Post-dose in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Score After 4 Weeks of Dosing in Each Crossover Period (Assessed by the Blinded-rater In-clinic at Visit 3 and Visit 6 of PART B).
The Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a clinimetric assessment of subjective and objective symptoms and signs of Parkinson's disease created by the Movement Disorder Society. The summary score used in this study for the primary objective and primary efficacy endpoint is Part III motor examination score. Each Part III item has a 0-4 rating, where 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. Higher MDS-UPDRS scores reflect worse motor function. MDS-UPDRS III is a total of 18 questions with 33 individual items, each item ranges from 0-4. The MDS-UPDRS III motor score is the summation of all these 33 individual item scores, and hence ranges from 0-132. Score drops over time imply improvement in motor function (higher values represent a worse outcome).
Time frame: Pre-dose to 90 minutes post-dose at Week 4 of each treatment period (Visit 3 and 6)
Population: Part B mITT population
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| SC (Subcutaneous Apomorphine) | Change From Pre-dose to 90 Mins. Post-dose in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Score After 4 Weeks of Dosing in Each Crossover Period (Assessed by the Blinded-rater In-clinic at Visit 3 and Visit 6 of PART B). | -13.78 Units on a scale |
| APL (APL-130277) | Change From Pre-dose to 90 Mins. Post-dose in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Score After 4 Weeks of Dosing in Each Crossover Period (Assessed by the Blinded-rater In-clinic at Visit 3 and Visit 6 of PART B). | -13.55 Units on a scale |
p-value: 0.894495% CI: [-3.16, 3.62]Mixed Models Analysis
Secondary
Durability of Effect, Defined as an Investigator Confirmed Full ON Within 30 Minutes Post Dose and at 90 Minutes Post-dose, After 4 Weeks of Dosing in Each Crossover Period (Assessed by the Blinded-rater In-clinic at Visit 3 and Visit 6 of PART B).
Investigator will confirm whether subject is OFF, Full ON or Partial ON , and note the time the subject changes from OFF to Partial ON or Full ON. The Investigator will also record the subject ON/OFF status (binary variable, Yes / No) prior to performing each MDS-UPDRS Part III assessment. Durability of effect is defined as an Investigator confirmed full ON within 30 minutes post-dose and at 90 minutes post-dose, after 4 weeks of dosing in each PART B crossover period. Response rate = % of subjects that achived full ON within the timeframe
Time frame: Within 30 minutes post-dose and at 90 minutes post-dose at Week 4 of each treatment period (Visit 3 and 6)
Population: Part B mITT population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SC (Subcutaneous Apomorphine) | Durability of Effect, Defined as an Investigator Confirmed Full ON Within 30 Minutes Post Dose and at 90 Minutes Post-dose, After 4 Weeks of Dosing in Each Crossover Period (Assessed by the Blinded-rater In-clinic at Visit 3 and Visit 6 of PART B). | 18.03 Percentage of participants |
| APL (APL-130277) | Durability of Effect, Defined as an Investigator Confirmed Full ON Within 30 Minutes Post Dose and at 90 Minutes Post-dose, After 4 Weeks of Dosing in Each Crossover Period (Assessed by the Blinded-rater In-clinic at Visit 3 and Visit 6 of PART B). | 17.74 Percentage of participants |
p-value: 0.777795% CI: [0.484, 2.637]generalized linear random effects model
Secondary
Patient Global Impression of Change (PGI-C): Subject Improvement of OFF Episodes, Defined as Very Much Better, Much Better or a Little Better After 4 Weeks of Dosing in Each Crossover Period (Assessed In-clinic at Visit 3 and Visit 6 of PART B).
The PGI-C is the patient reported outcome counterpart to the Clinical Global Impressions scale, (CGI), which was published in 1976 by the National Institute of Mental Health (US). It consists of one item taken from the CGI and adapted to the patient. The PGI-C is based on a 7-point scale, where a lower score is associated with higher symptom improvement. The scale is: Very much better Much better A little better No change A little worse Much worse Very much worse Subject improvement of OFF episodes is defined as very much better, much better or a little better at Week 4 in each PART B crossover period. Response rate= % of subjects who achieved improvement of OFF episodes
Time frame: At Week 4 of each treatment period (Visit 3 and 6, or Early Termination)
Population: Part B mITT population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SC (Subcutaneous Apomorphine) | Patient Global Impression of Change (PGI-C): Subject Improvement of OFF Episodes, Defined as Very Much Better, Much Better or a Little Better After 4 Weeks of Dosing in Each Crossover Period (Assessed In-clinic at Visit 3 and Visit 6 of PART B). | 77.14 Percentage of participants |
| APL (APL-130277) | Patient Global Impression of Change (PGI-C): Subject Improvement of OFF Episodes, Defined as Very Much Better, Much Better or a Little Better After 4 Weeks of Dosing in Each Crossover Period (Assessed In-clinic at Visit 3 and Visit 6 of PART B). | 83.10 Percentage of participants |
p-value: 0.392295% CI: [0.61, 3.53]generalized linear random effects model
Secondary
Subject Confirmed Durability of Effect, Defined as Subject Confirmed Full ON Within 30 Minutes Post-dose and at 90 Minutes Post-dose, After 4 Weeks of Dosing in Each Crossover Period (Assessed In-clinic at Visit 3 and Visit 6 of PART B).
Patients will confirm whether he/she is OFF, Full ON or Partial ON, and the staff will ask the subject to notify the staff when he/she changes from OFF to Partial ON or Full ON (binary variable, Yes / No) . Subject confirmed durability of effect is defined as subject confirmed full ON within 30 minutes post-dose and at 90 minutes post-dose, after 4 weeks of dosing in each crossover period (assessed in-clinic at V3 and V6 of PART B). Response rate = % subjects that achived full ON within the timeframe
Time frame: Week 4
Population: Part B mITT population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SC (Subcutaneous Apomorphine) | Subject Confirmed Durability of Effect, Defined as Subject Confirmed Full ON Within 30 Minutes Post-dose and at 90 Minutes Post-dose, After 4 Weeks of Dosing in Each Crossover Period (Assessed In-clinic at Visit 3 and Visit 6 of PART B). | 14.75 Percentage of participants |
| APL (APL-130277) | Subject Confirmed Durability of Effect, Defined as Subject Confirmed Full ON Within 30 Minutes Post-dose and at 90 Minutes Post-dose, After 4 Weeks of Dosing in Each Crossover Period (Assessed In-clinic at Visit 3 and Visit 6 of PART B). | 19.36 Percentage of participants |
p-value: 0.176995% CI: [0.759, 4.438]generalized linear random effects model
Secondary
Subject Preference for APL Treatment as Measured by the Subject Treatment Preference Questionnaire (TPQ), Planned After the Subject Had Completed Both APL-130277 and sc Apomorphine Treatment Regimens (Assessed In-clinic at Visit 6 of PART B)
The TPQ assessment of subject treatment preference was changed from being based on a visual analogue scale or VAS (Q9b)) to a 5-point Likert scale (Q9a). Subject reported preference for APL or SC was based on question Q9a or Q9b combined. For Q9a, responses were dichotomized as follows for statistical analysis: preference for APL (responses of either definitely or somewhat prefer APL) versus no preference for APL (responses of no preference, or somewhat/definitely prefer sc apomorphine). The VAS score was similarly dichotomized as preference for APL (score of \>0 to 50) versus no preference for APL (-50 to 0). If a subject responded to both Q9a and Q9b, then Q9a only was used.
Time frame: After 8 weeks of treatment (Visit 6)
Population: Part B mITT population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| SC (Subcutaneous Apomorphine) | Subject Preference for APL Treatment as Measured by the Subject Treatment Preference Questionnaire (TPQ), Planned After the Subject Had Completed Both APL-130277 and sc Apomorphine Treatment Regimens (Assessed In-clinic at Visit 6 of PART B) | 72.2 % of participants |
p-value: 0.0002binomial distribution with normal approx